welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
The Duchenne Registry
study id #: NCT02069756
condition: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
The Duchenne Registry is an online, patient-report registry for individuals with Duchenne and Becker muscular dystrophy and carrier females. The purpose of the Registry is to connect Duchenne and Becker patients with actively recruiting clinical trials and research studies, and to educate patients and families about Duchenne and Becker care and research. At the same time, The Duchenne Registry is a valuable resource for clinicians and researchers in academia and industry, allowing access to de-identified, aggregate datasets provided by patients and their families—information that is vital to advances in the care and treatment of Duchenne. The Duchenne Registry is a member of the TREAT-NMD Neuromuscular Network.
mechanism of action: No pharmaceutical intervention
last updated: February 25, 2020
start date: October 2007
estimated completion: October 2027
phase of development: N/A
size / enrollment: 10000
The Duchenne Registry (previously DuchenneConnect) was created in 2007 by Parent Project Muscular Dystrophy (PPMD), with assistance from the NIH, the CDC, and Emory Genetics. In early 2011, PPMD alone began financing the registry's operation and maintenance, and is the sole guardian of The Duchenne Registry and its material.
Questions may be addressed to the Duchenne Registry Coordinators at telephone 888-520-8675 or email@example.com. The Duchenne Registry Coordinators are certified genetic counselors who are available to answer questions regarding the registration process, genetic testing and counseling, and clinical trials and research studies.
- Genetic mutation [ Time Frame: Registrants are requested to update their medical history every 6-12 months, and they will be followed throughout their lifetime. ]
Genetic mutation data is collected by patient report and verified by curation/review of genetic test report when provided. Genetic test report is requested for each registrant and is required for participation in global DMD (TREAT-NMD) registry.
- Ambulation status [ Time Frame: Registrants are requested to update their medical history every 6-12 months, and they will be followed throughout their lifetime. ]
Ambulation status is assessed from several questions about mobility, ability to sit and stand, use of assistive devices, and age at full time wheelchair use.
• Eligible Sexes: all
• Diagnosis of Duchenne or Becker muscular dystrophy; Manifesting female carriers and asymptomatic female carriers also included in registry.
• Diagnosis of any other type of muscular dystrophy (including limb-girdle muscular dystrophy).
DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UKWith Duchenne muscular dystrophy (DMD) c...
A Device for Rapid, Painless, Bedside Muscle Evaluation of ChildrenThe purpose of this protocol is to perfo...
Duchenne Muscular Dystrophy < 18y in Norway: Genotype/Phenotype, Growth, Puberty, Bone Health and Quality of LifeThe study will give a consent based epid...
European Home Mechanical Ventilation RegistryThe European Home Mechanical Ventilation...
Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular DystrophyThis study is being performed as a post-...
PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award WinnersSOUTH PLAINFIELD, N.J., Sept. 6, 2019 ...
Antisense Therapeutics to commence muscular dystrophy trialsAntisense Therapeutics is planning to un...
An Update on Clinical Trial Innovation for Duchenne – a Master Protocol SharePPMD is committed to making research and...
Novo Biosciences achieves major milestones in moving trodusquemine into clinical trialsNovo Biosciences Inc., has achieved seve...